Skip to main content

Aiming to end hepatitis C. For good.

At AbbVie, we know it’s not just about science – it’s also about society. We are passionate about building creative partnerships around the world to tear down the barriers to hepatitis C (HCV) care and helping eliminate the virus in some of the world’s most vulnerable communities. Global elimination is possible, and every patient cured* brings us closer to that goal.

An inside look at discovering a medicine for hepatitis C

700 people. 20 years. 1 medicine. In this episode of Discovery Files, veteran scientists Warren Kati, PhD, and Seble Wagaw detail the exhilarating journey to uncover a treatment for people with HCV.

Discovery Files: Hepatits C Virus

Our commitment to hepatitis C elimination around the world

When it comes to global HCV elimination, time matters. We are less than 10 years away from the World Health Organization’s (WHO) 2030 goal for HCV elimination. Elimination is achievable by then, but the HCV patient community is still up against some enormous challenges. 

Many of the "missing millions" living with HCV are at the margins of society - without health systems designed to reach or support them. At AbbVie, we see it as our responsibility to accelerate efforts to help simplify the system. While much work remains, what's been accomplished has paved the way towards elimination.

Learn more about the Road to HCV Elimination.

Micro-Elimination Overview

We are working with the hepatitis C community to support an estimated 300 targeted, local micro-elimination projects worldwide to move us closer to a world free of hepatitis C. These projects are helping fuel new models of care from the prisons of Portugal to the remote mountains of South Korea. These are a select few of the AbbVie efforts being conducted around the world:

AbbVie Israel

Road to the Cure

In Israel, an effort to map the most frequented locations of people who inject drugs is helping healthcare providers bring laboratory services and hepatitis C treatment to places where these patients feel comfortable.

AbbVie Japan

Arcadia Hiroshima

In Japan, a partnership between local and regional governments is helping to improve hepatitis C awareness among general practitioners and non-specialists to support the HCV referral system and link more patients to care.

AbbVie Australia

No C in Blacktown

Australia must increase testing and improve linkage to care in order to eliminate HCV by 2030, new research shows. To help, one Australian project is replicating a successful model of diabetes screening and treatment at Blacktown Hospital in Western Sydney to improve HCV awareness among at risk groups including people who inject drugs.

The World Health Organization's 2030 goal to eliminate hepatitis C is less than 10 years away. We all have a part to play. Download our PDF to learn more about how we’re moving fast and working hard to help eliminate hepatitis C.

Transformative partnerships

We all have a part to play in making hepatitis C elimination the next public health success story, and transformative partnerships are essential to helping solve some of the most pressing challenges. Hear what some of AbbVie’s partners in eliminating hepatitis C have to say about it:

achieve hcv elimination video
Video still of man in suit talking to camera
rachel video

Removing barriers to care

Addressing barriers to hepatitis C care will mean uniting all of us — healthcare providers, patients, advocates, caregivers, healthcare systems — in a collective effort to overcome the obstacles. Hear how lack of education, stigma, discrimination, and global challenges can prevent people affected by hepatitis C from accessing care:

Man in suit sitting down and mid-sentence
dr pol video

Urgency to act

We know curing hepatitis C is not just about science – it’s also about society. While many of the ‘missing millions’ may live at the margins and be harder to reach, acting now to help eliminate HCV globally is critical for all patients, regardless of location or status. Hear why:

Video still of man in suit talking to camera

Partnering to solve pressing challenges

AbbVie has a long history of working with stakeholders to increase access to our medicines worldwide, including licensing our medicine to quality-assured providers of generics so treatments are available for individuals in more than 90 low- and middle-income countries and territories.

 

* Patients who achieve a sustained virologic response at 12 weeks post treatment (SVR12) are considered cured of hepatitis C.